Summary: In this executive summary, discover how Catalent’s Manufacturing by Design (MbD) strategy can help achieve efficiencies, drive cost savings, and develop and implement a robust, reproducible manufacturing plan for late-stage and commercial launch.

Summary: Watch this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technologies and strategies that drive an optimized...

Summary: In this webinar, we explore the drivers for process characterization and late-phase development including improving process understanding, enhancing robustness, and assurance that it delivers...

Summary: Process validation, including process characterization, is a critical step in the successful commercialization of a new biopharmaceutical on its path to commercialization. As the program approaches commercial launch...

Summary: Discover how a platform process for the manufacturing of plasmid DNA is helpful for all stages, from screening candidates in preclinical studies to large-scale production for late-stage and commercial needs.

Summary: iPSCs are a critical starting material and enable the availability of next-generation cell therapies for broad patient populations. Learn more about Catalent’s GMP iPSC capabilities including reprogramming, differentiation, and cell banking, and how they can create a path to make cell therapies more accessible.

Summary: In this article, experts detail how drug developers overcome obstacles that may complicate the launch of orphan drugs in order to meet their own needs and the needs of patients.

Summary: Catalent’s SMARTag platform technology offers ADC and biologics innovators a toolkit to develop optimized ADCs and bioconjugates.

Summary: In this webinar, we explore the considerations that need to be taken during development to ensure manufacturing processes and our facilities can support...

Summary: In this on-demand webinar, hear our product development expert discuss Catalent’s UpTempo Virtuoso AAV platform process, a scalable, CGMP-ready platform process that can significantly reduce the time from gene to clinic.